Compass Pathways (CMPS)

• Market cap: $360M
• 1 day: 0.52%
• 5 days: 11.78%
• 1 month: -3.47%
• 3 months: -39.50%
• 6 months: -43.95%
• Year to date: -6.27%
• 1 year: -58.88%
• 5 years: -86.59%
• 10 years: -86.59%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Employees: 186

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

60% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 15

16% more capital invested

Capital invested by funds: $179M [Q2] → $208M (+$28.9M) [Q3]

7% more funds holding

Funds holding: 121 [Q2] → 129 (+8) [Q3]

4.52% more ownership

Funds ownership: 43.4% [Q2] → 47.92% (+4.52%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

4% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 28

46% less call options, than puts

Call options by funds: $4.21M | Put options by funds: $7.82M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 208% upside
• Avg. target: $30 671% upside
• High target: $60 1,442% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

RBC Capital Leonid Timashev 40% 1-year accuracy 18 / 45 met price target	363% upside $18	Outperform Reiterated	15 Jan 2025
HC Wainwright & Co. Patrick Trucchio 33% 1-year accuracy 52 / 157 met price target	1,442% upside $60	Buy Maintained	1 Nov 2024
Maxim Group Jason McCarthy 37% 1-year accuracy 11 / 30 met price target	208% upside $12	Buy Maintained	1 Nov 2024